Achilles W et al. The in-vivo effect of sodium-potassium citrate on the crystal growth rate of calcium oxalate and other parameters in human urine. Urol Res 1990; 18, 1:1-6.
Axellson B, Piscator M. Renal change after prolonged exposure to cadmium. Arch Environ Health 1969; 12:360-72.
Anderson CK. Renal histological changes in stone formers and non-stone formers, in; A Hodgkinson, BEC Nordin, Eds., Proc Renal Stone Res Sympos. London, Churchill, 1969:133-6.
Anton R, Haag-Berrurier M. Therapeutic use of natural anthraquinone for other than laxative actions. Pharmacology 1980; 20: 104-12.
Atkins GL et al. Quantitative aspects of ascorbic acid metabolism in man. J Biol Chem 239:2975-80, 1964.
Azowrv L, Garti N, Perlberg S, Sarig S. May enzyme achvity in urine play a role in kidney stone formation? Urol Res 1982; 10: 185-89.
Azoury R et al. Retardation of calcium oxalate precipitation by glutamic-oxaloacetic-transaminase activity. Urol Res 1982; 10:169.
Baggio B et al. Correction of erythrocyte abnormalities in idiopathic calcium-oxalate nephrolithiasis and the reduction of urinary oxalate by oral glycosaminoglycans. Lancet 1991;338:403-5.
Bek-Jensen H et al. Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations in urine? Urol Res 1996; 24:67-71.
Bell R, Eldrid M, Watson F. The influence of NaCl and KCl on urinary calcium excretion in healthy young women. Nutr Res 1992; 12:17-26.
Bichler KH et al. Influence of vitamin A deficiency on the excretion of uromucoid and other substances in the urine of rats. Clin Nephrol 1983; 20:32-9.
Berg W, Hesse A, Hensel K, et al. Influence of anthraquinones on the formation of urinary calculi in experimental animals. Urologe A 1976; 15(4): 188-91.
Blacklock NJ. The pattern of urolithiasis in the Royal Navy, in A Hodgkinson & BEC Nordin, Eds. Renal Stone Research Symposium. London, J & A Churchill, 1969:33-47.
Blacklock NJ. Sucrose and idiopathic renal stone. Nutr Health 5: 9-17, 1987.
Breslau NA et al. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 66; 1:140-6, 1988.
Brinkley LJ, Gregory J, Pak CYC. A further study of oxalate bioavailability in foods. J Urol 144:94-6, 1990.
Brockis JG et al. The effect of vegetable and animal protein diets on calcium, urate and oxalate excretion. Br J Urol 54; 6:590-3, 1982.
Buck AC, Davies RL, Harrison T. The protective role of eicosapentaenoic acid [EPA] in the pathogenesis of nephrolithiasis. J Urol 146; 1:188-94, 1991.
Buck AC et al. The treatment of idiopathic recurrent urolithiasis with fish oil and evening primrose oil: a double blind study. Abstract. J Urol 149:253A, 1993.
Buck AC et al. The prevention of experimental nephrocalcinosis with eicosapentaenoic acid and evening primrose oil. Abstract. J Urol 149:499A, 1993.
Burtis WJ, Gay L, Insogna KL, et al. Dietary hypercalciuria in patients with calcium oxalate kidney stones. Am J Clin Nutr 60:424-9, 1994.
Butz M et al. Dietary influenceon serum and urinary oxalate in healthy subjects and oxalate stone formers. Urol Int 35:309-15, 1980.
Coe F, Moran E, Kavalich A. The contribution of dietary purine over-consumption to hyperuricosuria in calcium oxalate stone formers. J Chron Dis 29: 793-800, 1976.
Conte A et al. Uric acid and its relationship with glycosaminoglycans in normal and stone-forming subjects. Nephron 52; 2:162-5, 1989.
Conte A et al. The relation between orthophosphate and pyrophosphate in normal subjects and in patients with urolithiasis. Urol Res 17;3:173-5, 1989.
Conte A et al. On the relation between citrate and calcium and normal and stone-former subjects. Int J Nephrol 21; 4:369-73, 1989
Crawhall JC et al. Conversion of glycine to oxalate in a normal subject. Lancet ii:810, 1959
Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328; 12:833-8, 1993.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 155:61847-51, 1996.
Dharmsathaphorn K, Freeman D, Binder H, Dobbins J. Increased risk of nephrolithiasis in patients with steatorrhea. Dig Dis Sci 27: 401-405, 1982.
Dance N et al. The excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase by patients with renal disease. Clin Chem Acta 27:87-92, 1970,
DeFronzo RA et al. The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 55:845-55, 1975.
Ebisuno S, Morimoto S, Yoshida T, et al. Rice-bran treatment for calcium stone formers with idiopathic hypercalciuria. Br J Urol 58:592-5, 1986.
Elizabeth JE, Carter NJ. Potassium citrate mixture: soothing but not harmless? Br Med J Clin Res; 295:993, 1987.
Elliot JS, Ribeiro ME. The urinary excretion of trace metals in patients with calcium oxalate urinary stone. Invest Urol 10:253-5, 1973.
Eusebio E, Elliot JS. Effect of trace metals on the crystallisation of calcium oxalate. Invest Urol 4:431, 1967.
Fan J Shen SJ. The role of Tamm-Horsfall mucoprotein in calcium oxalate crystallization. N-acetylcysteine - a new therapy for calcium oxalate urolithiasis. Br J Urol 74; 3:288-93, 1994.
Fellstrom B, Danielson BG, Karlstrom B, et al. The influence of a high dietary intake of purine-rich animal protein on urinary urate excretion and supersaturation in renal stone disease. Clin Sci 64:399-405, 1983.
Fellström B et al. Dietary history and dietary records in renal stone patients and control. Urol Res 12:58, 1984;
Firth WA, Norman RW. The effects of modified diets on urinary risk factors for kidney stone disease. J Can Diet Assoc 51:404-8, 1990.
François B et al. Inhibitors of urinary stone formation in 40 recurrent stone formers. Br J Urol 58; 5:479-83, 1986.
Gershoff SN, Prien EL. Excretion of urinary metabolites in calcium oxalate urolithiasis: Effect of tryptophan and vitamin B6 administration. Am J Clin Nutr 8:812, 1960.
Gershoff S, Prien EL. Effect of daily MgO and vitamin B6 administration to patients with recurring calcium oxalate kidney stones. Am J Clin Nutr 20:393-399, 1967.
Gershoff SN, McGandy RB. The effects of vitamin A-deficient diets containing lactose in producing bladder calculi and tumors in rats. Am J Clin Nutr 34:483, 1981.
Giannini L, Nobile M, Castrignano R, et al. Possible link between vitamin D and hyperoxaluria in patients with renal stone disease. Clin Sci 84:51-4, 1993.
Gibbs DA, Watts RWE. The action of pyridoxine in primary hyperoxaluria. Clin.Sci 38:277-86, 1970.
Goldfarb S. Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiasis. Kidney Int 34:544-55, 1988.
Goldschmidt P et al. Urinary stones and dietary practice: A comparative study based on 600 stones in Alsace, Argentina and Laos. Fortschr Urol Nephrol 22:23-6, 1984
Green TJ, Whiting SJ. Potassium bicarbonate reduces high protein-induced hypercalciuria in adult men. Nutr Res 14:991-1002, 1994.
Griffith H, O'Shea B, Kevany J, McCormick J. A control study of dietary factors in renal stone formation. Br J Urol 53: 416 420, 1981.
Grimm U et al. Studies on tryptophan metabolism in calcium oxalate urolithiasis. Z Urol Nephrol 81; 5:299-303, 1988.
Güszek J. The effect of glucose intake on urine saturation with calcium oxalate, calcium phosphate, uric acid and sodium urate. Int Urol Nephrol 20; 6:657-64, 1988.
Hallson PG, Rose G, Sulaiman SM. Magnesium reduces calcium oxalate crystal formahon in human whole unne. Clin Sci 62: 17-19, 1982.
Harrison AR et al. Hyperoxaluria and recurrent stone formation apparently cured by short course of pyridoxine. Br Med J 282: 2097-8, 1981.
Harvey JA, Zobitz MM, Pak CYC. Calcium citrate: Reduced propensity for the crystallization of calcium oxalate in urine resulting from induced hypercalciuria of calcium supplementation. J Clin Endocrinol Metabol 61, 6:1223-5, 1985.
Hasling C, Sondergaard K, Charles P, Mosekilde L. Calcium metabolism in postmenopausal osteoporotic women is determined by dietary calcium and coffee intake. J Nutr 122; 5:1119-26, 1992.
Heaney RP, Recker RR. Effects of nitrogen, phosphorus, and caffeine on calcium balance in women. J Lab Clin Med 99: 46-55, 1982.
Heyburn PJ et al. Phosphate treatment of recurrent calcium stone disease. Nephron 32, 4:314-19, 1982.
Hiatt RA, Ettinger B, Caan B, et al. Randomized controlled trial of a kidney stones calcium oxalate 2 low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 144; 1:25-33, 1996.
Hodgkinson A. The urinary excretion of oxalic acid in nephrolithiasis. Proc R Soc Med 51:970-1, 1958.
Hodgkinson A. Proc Roy Soc Med 51:970, 1958.
Hollingbery PW et al. Effect of dietary caffeine and aspirin on urinary calcium and
hydroxyproline excretion in pre- and postmenopausal women. Fed Proc 44:1149, 1985.
Holmes RP et al. Dietary oxalate and its intestinal absorption. Scanning Microscopy 9; 4:1109-20, 1995.
Hosking DH et al. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 130:1115-8, 1983.
Hughes J, Norman RW. Diet and calcium stones. Can Med Assoc J 146; 2:137-43, 1992.
Hunt CD, Herbel JL, Nielsen FH. Metabolic responses of postmenopausal women to supplemental dietary boron and aluminum during usual and low magnesium intake: Boron, calcium, and magnesium absorption and retention and blood mineral concentrations. Am J Clin Nutr 65:803-13, 1997.
Iguchi M et al. Nutritional risk factors in calcium stone disease in Japan. Urol Int 39:32-5, 1984.
Insogna KL et al. Trichlormethiazide and oral phosphate therapy in patients with absorptive hypercalciuria. J Urol 141; 2:269-74, 1989.
Issels RD et al. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol 37:881, 1988.
Jaeger P. et al. Idiopathic hyperoxaluria "cured" by a short course of pyridoxine B6: Further evidence for B6-deficiency. Abstract. Clin Res 34, 2:546A, 1962.
Johansson G et al. Biochemical and clinical effects of prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol 124; 6:770-4, 1980.
Johansson G, Backman U, Danielson B et al. Magnesium metabolism in renal stone formers. Effects of therapy with magnesium hydroxide. Scand J Urol Nephrol 53: 125-130, 1980.
Khanniazi MK, Khanam A, Japper Naqvi SA, Sheikh MA. Study of potassium citrate treatment of crystalluric nephrolithiasis. Biomed Pharmacother 47:25-8, 1993.
Johansson G. Magnesium and renal stone disease. Acta Med Scand; suppl 661:13-18, 1982
Johansson G et al. Effects of magnesium hydroxide in renal stone disease. J Am Coll Nutr 1, 2:179-85, 1982.
Kaneko K et al. Urinary calcium and calcium balance in young women affected by high protein diet of soy protein isolate and adding sulfur-containing amino acids and/or potassium. J Nutr Sci Vitaminol Tokyo 36; 2:105-16, 1990.
Kasidas GP et al. Mild but clinically significant metabolic hyperoxaluria and its' response to pyridoxine, in H von G Gasser, Wahlensieck W, Eds. Pathogenese und Klinik Harnstein XI. Darmstadt, Steinkopff Verlag, 1985: 394-9.
Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes May Reduce the Risk of Calcium Oxalate Kidney Stones. J Am Soc Nephrol 2008; 19: 1197-1203.
Kitamura T et al. Urinary calcium and phosphorus excretion and their relationship in calcium-containing urinary stone formers. Nippon Hinyokika Gakkai Zasshi 80; 2:197-203, 1989.
Lamden MP, Chrystowski GA. Urinary oxalate excretion by man following ascorbic acid ingestion. Proc Soc Exp Biol Med 85:190-2, 1954.
Lemann J, Piering W, Lennon E. Possible role of carbohydrate induced hypercalciuria in calcium oxalate kidney-stone formation.New Engl J Med 1969; 280: 232-237, 1969.
Lennon EJ et al. A possible mechanism for diminished renal tubular calcium and magnesium reabsorption after glucose ingestion. Abstract. Clin Res 16:388, 1968.
Li MK et al. Effects of magnesium on calcium oxalate crystallization. J Urol 133:123, 1985.
Li MK et al. Does sucrose damage kidneys? Br J Urol 58; 4:353-7, 1986.
Liebman M, Chai W. Effect of dietary calcium on urinary oxalate excretion after oxalate loads. Am J Clin Nutr 65: 1453 1459 , 1997.
Lindberg J, Harvey J, Pak CYC. Effect of magnesium citrate and magnesium oxide on the crystallization of calcium salts in urine: changes produced by food-magnesium interaction. J Urol 143; 2:248-51, 1990.
Lyon E, Borden T, Ellis J, Vermeulen C. Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets. Invest Urol 4: 133-142, 1966.
Massey LK, Berg TA. The effect of dietary caffeine on urinary excretion of calcium, magnesium, phosphorus, sodium, potassium, chloride and zinc in healthy males. Nutr Res 5:1281-4, 1985.
Massey LK. Dietary salt, urinary calcium, and kidney stone risk. Nutr Rev 53: 131-139, 1995.
Massey LK, Sutton RAL. Acute caffeine effects on urine composition and calcium kidney stone risk in calcium stone formers. Journal of Urology 2004; 172(2):555-558.
Mates J. External factors in genesis of urolithiasis, in A Hodgkinson, BEC Nordin, Eds. Renal Stone Research Symposium. London, J & A Churchill, 1969:59-64
McGeown MG. The urinary excretion of amino acids in calculus patients. Clin Sci 18:185, 1959.
Menon M, Mahle CJ. Urinary citrate excretion in patients with renal calculi. J Urol 129, 6:1158-60, 1983.
Michelacci YM et al. Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Kidney Int 36; 6:1022-8, 1989.
Milliner D, Eickholt J, Berstrahl E, et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331; 23:1553-8, 1994.
Mitwalli A et al. Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. Int Urol Nephrol 20; 4:353-9, 1988.
Modlin M. Urinary phosphorylated inositols and renal stone. Lancet ii:1113-14, 1980.
Modlin M et al. Dietary structure and urinary composition in a stone free population, in LH Smith et al, Eds. Urolithiasis: Clinical and Basic Research. New York, Plenum Press, 1981: 337-42.
Morgan LJ, Liebman M, Broughton KS. Caffeine-induced hypercalciuria and renal
prostaglandins: effect of aspirin and n-3 polyunsaturated fatty acids. Am J Clin Nutr 60:362-8, 1994.
Morris JE et al. Dietary refined carbohydrate and urinary mineral excretion. J R Nav Med Serv 64; 2:110-18, 1978.
Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 22: 292-6, 1982.
Murthy MS, Farooqui S, Talwar HS, et al. Effect of pyridoxine supplementation on recurrent stone formers. Int J Clin Pharmacol Ther Toxicol 20; 9: 434-7, 1982.
Nakagawa Y, Margolis H, Yokoyama S et al. Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chem 256: 3936-3944 , 1981.
Nicar MJ et al. Low urinary citrate excretion in nephrolithiasis. Urology 21:8-14, 1983.
Nikkilä MT. Urinary glycosaminoglycan excretion in normal and stone-forming subjects: Significant disturbance in recurrent stone formers. Urol Int 443:157-9, 1989.
Noronha IL et al. Rice bran in the treatment of idiopathic hypercalciuria in patients with urinary calculosis.Rev Paul Med 107; 1:19-24, 1989.
Ohkawa T, Ebisuno S, Kitagawa M, et al. Rice bran treatment for patients with hypercalciuric stones: experimental and clinical studies. J Urol 132; 6:1140-5, 1984.
Pak CYC et al. Dietary management of idiopathic calcium urolithiasis. J Urol 131:850-2, 1984.
Pak CYC et al. Long term treatment of calcium nephrolithiasis with potassium citrate. J Urol 134, 1:11-19, 1985.
Pak CY, Fuller C. Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med 104, 1:33-7, 1986.
Pak CY, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 146, 5:863-7, 1986.
Palmqvist E, Tiselius HG. Phosphate treatment of patients with renal calcium stone disease. Urol Int 43; 1:24-8, 1988.
Preminger GM et al. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with renal tubular acidosis. J Urol 134; 1:20-3, 1985.
Preminger GM et al. Alkali action on the urinary crystallization of calcium salts: Contrasting responses to sodium citrate and potassium citrate. J Urol 139; 2:240-2, 1988.
Preminger G et al. Hypomagnesiuric hypocitraturia. An apparent new entity for calcium nephrolithiasis. J Lithotripsy Stone Dis, 1990.
Prien EL, Gershoff S. Magnesium oxide-pyridoxine therapy for recurring calcium oxalate urinary calculi. J Urol 112:509-512, 1974.
Rangnekar GV, Gamur MS. Serum and urinary zinc levels in urolithiasis. Br J Urology 71:527-9, 1993.
Rao N, Gordon C, Davis D, Blacklock N. Are stone formers maladaptive to refined carbohydrates? Br J Urol 1982; 54: 575-577, 1982.
Rao RN et al. Dietary management of urinary risk factors in renal stone formers. Br J Urol 54:578-83, 1982.
Rao PN. Dietary habit and urolithiasis, in DLJ Freed, Ed. Health Hazards of Milk. London, Baillière Tindall, 1984.
Rao PN et al. Is salt restriction necessary to reduce the risk of stone formation? Urol Res 12:56-7, 1984.
Rao PHN et al. Metabolic response to refined carbohydrates in idiopathic urolithiasis. Urol Int 39; 3:165-9, 1984;
Rattan VF, Sidhu H, Vaidyanathan S, et al. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers. Urol Res 22; 3:161-5, 1994.
Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc 95:791-7, 1995.
Revusova V et al. The significance of oxaluria reduction by pyridoxine in prevention of calcium oxalate nephrolithiasis. Cas Lek Ces 121; 6:163-6, 1982.
Riley K. The biological efficacy of aloes. J John Bastyr Coll Nat Med 2: 18-27, 1981.
Ringsdorf WM Jr, Cheraskin E. Nutritional aspects of urolithiasis. South Med J 74:41-4, 1981.
Rivers JM. Safety of high level vitamin C ingestion. Int J Vitamin Nutr Res 30: 95-102, 1989.
Robertson WG et al. The effect of high animal protein intake on the risk of calcium stone-formation in the urinary tract. Clin Sci 57:285-8, 1979.
Robertson WG, Peacock M, Heyburn PJ, et al. Should recurrent calcium oxalate stone formers become vegetarian? Br J Urol 51:427-31, 1979.
Robertson WG, Peacock M, Heyburn PJ, et al. Epidemiological risk factors in calcium stone disease. Scand J Urol Nephrol 53; suppl:15-28, 1980.
Robertson WG, Peacock M, Marshall DH. The prevalence of urinary stone disease in vegetarians. Eur Urol 8:334, 1982.
Robertson WG. Diet and calcium stones. Miner Electrolyte Metab 13:228-34, 1987.
Rodgers AL. Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Urol Int 58; 2:93-9, 1997.
Rose GA, Westbury EJ. The influence of calcium content of water, intake of vegetables, fruit and of other food factors upon incidence of renal calculi. Urol Res 3:61-6, 1975.
Rushton H, Spector M. Effects of magnesium deficiency on intra tubular calcium oxalate formation and crystalluria in hyperoxaluric rats. J Urol 127: 598-604, 1982.
Samaan K. The pharmacological basis of drug treatment of spasm of the ureter or bladder and of ureteral stone. Br J Urol 5: 213 224, 1933.
Saez G et al. The production of free radicals during the auto-oxidation of cysteine and their effect on isolated rat hepatocytes. Biochim Biophys Acta 719:24, 1982.
Schneider HJ. Preventing the recurrence of kidney stones with Farnolith Bran preparation, in Walker VR, RAL Sutton, ECB Cameron, et al, Eds. Urolithiasis. New York, Plenum Press, 1989:871.
Scott R, Cunningham C, McLelland A et al. The importance of cadmium as a factor in calcified upper urinary tract stone disease - a prospective 7-year study. Br J Urol 54: 584-589, 1982.
Seltzer MA et al. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 156:907-9, 1996.
Shaw P, Williams G, Green N. Idiopathic hypercalciuria: its control with unprocessed bran. Br J Urol 1980; 52: 426 429
Shuster J et al. Soft-drink consumption and urinary-stone recurrence: a randomized prevention trial. J Clin Epidemiol 45:911-16, 1992.
Sierakowski R et al. Stone incidence as related to water hardness in different geographical regions in the United States. Urol Res 7:157-60, 979.
Shuster J et al. Water hardness and urinary stone disease. J Urol 128:422-5, 1982.
Shah PJ, Green NA, Williams G. Unprocessed bran and its effect on urinary calcium excretion in idiopathic hypercalciuria. Br Med J 281:426, 1980.
Shah PJ et al. Idiopathic hypercalciuria: its control with unprocessed bran. Br J Urol 52; 6:426-9, 1980.
Silver J et al. Sodium-dependent idiopathic hypercalciuria in renal-stone formers. Lancet ii:484-6, 1983.
Schmiedl A, Schwille P. Magnesium status in idiopathic calcium urolithiasis -An
orientational study in younger males. Eur J Clin Chem Clin Biochem 34:393-40, 1996.
Smith LH et al. Orthophosphate treatment in calcium urolithiasis. Scand J Urol Nephrol Suppl 53:253-63, 1980.
Takahasi E. The magnesium:calcium ratio in the concentrated urines of patients with calcium oxalate calculi. Invest Urol 10:147, 1972.
Thom J, Morris J, Bishop A, Blacklock NJ. The influence of refined carbohydrate on urinary calcium excretion. Br J Urol 1978; 50: 459 464; 1978.
Thind SK et al. Role of vitamin B6 in oxalate metabolism in urolithiasis. Abstract. Am J Clin Nutr 32; 6:20, 1979
Tulloch I, Smellie WS, Buck AC. Evening primrose oil reduces urinary calcium excretion in both normal and hypercalciuric rats. Urol Res 22; 4:227-30, 1994.
Ulmann A, Aubert J, Bourdeau A et al. Effects of weight and glucose ingestion on urinary calcium and phosphate excretion. Implications for calcium urolithiasis. J Clin Endo Metab 54: 1063-1067, 1982.
Unwin R, Wrong O, Cohen E, et al. Grand round: unraveling the molecular mechanisms of kidney stones. Lancet 1996;348: 1561-5.
Urivetzky M, Kessaris K, Smith A. Ascorbic acid overdosing: A risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147: 1215-18.
Vahlensieck W et al. Nutrition history of recurrent calcium oxalate stone formers pre- and post-dietary, in R Ryall et al, Eds. Urinary Stone. London, Churchill Livingstone, 1984: 41-6.
Wandzilak TR, D'andre SD, Davis PA, Williams HE. Effect of high dose vitamin C on urinary oxalate levels. J Urol 1994; 151:834-837.
Whalley NA et al. Long-term effects of potassium citrate therapy on the formation of new stones in groups of recurrent stone formers with hypocitraturia. Br J Urol 1996; 78:10-14.
Will EJ, Bijvoet OL. Primary oxalosis: Clinical and biochemical response to high-dose pyridoxine therapy. Metabolism 1979; 28; 5:542-48.
Wolinsky I, Fosmire GJ. Calcium metabolism in aged mice ingesting a lysine-deficient diet. Gerontology 1982; 28; 3:156-62.
Wunderlich W. Aspects of the influence of magnesium ions on the formation of calcium oxalate. Urol Res 1981;9:157-160.
Yoshida O. Epidemiology of urolithiasis in Japan. Jap J Urol 1979; 70: 975-83.
Yudkin J et al. Effects of high dietary sugar. Br Med J 1980; 281: 1396.
Zarembski PM, Hodgkinson. Some factors increasing the urinary excretion of oxalate in man. Clin Chim Acta 1969; 25: 1-10.
Zechner O, Latal D, Pfluger H, Scheiber V. Nutritional risk factors in urinary stone disease. J Urol 1981; 125: 51-55.
